Seres Therapeutics, Inc.
Veridion Score
Composite trend over time
Why is MCRB moving today?
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for MCRB.
MCRB insider activity
Seres Therapeutics, Inc.
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for MCRB.
MCRB contract awards, year to date.
Public federal awards linked to this ticker.
MCRB lobbying filings, year to date.
Registered lobbying filings matched to Seres Therapeutics, Inc..